JAGX Jaguar Health Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: JAGX

Price (delayed)

$0.3137

Market cap

$86.65M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.79

Enterprise value

$117.27M

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating ...

Highlights
JAGX's quick ratio has surged by 138% year-on-year and by 51% since the previous quarter
The EPS has soared by 95% YoY and by 41% QoQ
The net income has increased by 13% YoY but it has decreased by 4% QoQ
Jaguar Health's gross profit has decreased by 22% YoY and by 13% QoQ
The company's revenue fell by 18% YoY and by 9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://jaguar.health
Peers: ZTS LFVN

Key stats

What are the main financial stats of JAGX
Market
Shares outstanding
276.22M
Market cap
$86.65M
Enterprise value
$117.27M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.21
Price to sales (P/S)
0.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.01
Earnings
Revenue
$9.76M
EBIT
-$34.92M
EBITDA
-$32.53M
Free cash flow
-$33.24M
Per share
EPS
-$1.79
Free cash flow per share
-$1.44
Book value per share
$0.1
Revenue per share
$0.42
TBVPS
$1.33
Balance sheet
Total assets
$50.76M
Total liabilities
$45.87M
Debt
$37.09M
Equity
$4.96M
Working capital
$13.98M
Liquidity
Debt to equity
7.48
Current ratio
2
Quick ratio
0.62
Net debt/EBITDA
-0.94
Margins
EBITDA margin
-333.3%
Gross margin
79.1%
Net margin
-423.1%
Operating margin
-351.3%
Efficiency
Return on assets
-80.5%
Return on equity
-855.6%
Return on invested capital
-99.7%
Return on capital employed
-94.9%
Return on sales
-357.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

JAGX stock price

How has the Jaguar Health stock price performed over time
Intraday
8.17%
1 week
74.28%
1 month
323.35%
1 year
-44.77%
YTD
107.2%
QTD
248.94%

Financial performance

How have Jaguar Health's revenue and profit performed over time
Revenue
$9.76M
Gross profit
$7.72M
Operating income
-$34.29M
Net income
-$41.3M
Gross margin
79.1%
Net margin
-423.1%
JAGX's operating margin is down by 22% YoY and by 15% from the previous quarter
Jaguar Health's gross profit has decreased by 22% YoY and by 13% QoQ
The company's revenue fell by 18% YoY and by 9% QoQ
JAGX's net margin is down by 14% since the previous quarter and by 7% year-on-year

Growth

What is Jaguar Health's growth rate over time

Valuation

What is Jaguar Health stock price valuation
P/E
N/A
P/B
3.21
P/S
0.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.01
The EPS has soared by 95% YoY and by 41% QoQ
The price to book (P/B) is 50% higher than the last 4 quarters average of 2.0 but 44% lower than the 5-year quarterly average of 5.4
The price to sales (P/S) is 88% lower than the 5-year quarterly average of 5.9 but 38% higher than the last 4 quarters average of 0.5
The company's revenue fell by 18% YoY and by 9% QoQ

Efficiency

How efficient is Jaguar Health business performance
The ROE is up by 38% YoY and by 26% QoQ
The return on invested capital has increased by 26% year-on-year and by 6% since the previous quarter
The ROS fell by 24% QoQ and by 23% YoY
The company's return on assets rose by 15% YoY but it fell by 2.3% QoQ

Dividends

What is JAGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for JAGX.

Financial health

How did Jaguar Health financials performed over time
JAGX's total assets is 11% greater than its total liabilities
Jaguar Health's current ratio has soared by 170% YoY and by 13% from the previous quarter
JAGX's quick ratio has surged by 138% year-on-year and by 51% since the previous quarter
The debt to equity has soared by 114% YoY but it has plunged by 71% from the previous quarter
JAGX's debt is up by 6% year-on-year and by 4.4% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.